Scrip Awards 2018 Shortlist
Congratulations to all of our finalists for 2018.
Masters Specialty Pharma's Best Company in an Emerging Market Award
Beximco Pharmaceuticals
Biocon
CinnaGen Pharmaceutical Group
Hutchison China MediTech (Chi-Med)
Mundipharma Singapore
WuXi Biologics
Best Contract Research Organization – Full-Service Providers
CMIC Group
Covance
ICON
IQVIA
PAREXEL
Worldwide Clinical Trials
Best Contract Research Organization – Specialist Providers
Cytel
Illingworth Research Group
PHASTAR
Quanticate
Simbec-Orion
Tioga Research
Best Technological Development in Clinical Trials - Clinical Sponsor-focused
Cytel’s OK GO software
Novartis’s Nerve Live
Covance’s Xcellerate CRA Dashboard
PAREXEL’s Perceptive Cloud
IQVIA’s Mobile SVR application
ICON’s FIRECREST Pre-Screen
Best Technological Development in Clinical Trials - Tech Sponsor-focused
Phesi’s real-time data collection and analysis
CluePoints’ Intelligent Central Statistical Monitoring Solution
Bioclinica’s Bioclinica Clinical Adjudication
ERT’s Advanced Imaging Technology Solution
Ergomed/PrimeVigilance/Automation Anywhere’s robotic process automation software
Medidata’s Medidata Rave Engage
Community Partnership of the Year Award – Sponsored by Medidata Solutions
AstraZeneca’s Mentoring Team
Beximco Pharma with DSM Nutritional Products and Sight & Life Global Nutrition Research Institute to improve nutrition in rural Bangladesh
IQVIA India’s Race for 7 with the Organization for Rare Diseases India
Oxford PharmaGenesis’ Open Pharma
Best Use of Real-World Evidence
Biogen/ICON’s New insights into the burden and costs of multiple sclerosis in Europe
ICON/Vertex’s study of lumacaftor/ivacaftor lung function decline in patients with cystic fibrosis
IQVIA/Bristol-Myers Squibb’s I-O Optimise collaboration in patients with a thoracic malignancy
PAREXEL, EMD Serono (a business of Merck KGaA, Darmstadtr, Germany), MedCodeWorld, and Intermountain Healthcare's Multiple Sclerosis Algorithms Development and Validation project
Neurocrine BioSciences’s RE-KINECT prospective real-world dyskinesia screening study and registry in patients taking antipsychotics
Best Partnership Alliance
Bicycle Therapeutics and Bioverativ for hemophilia and sickle cell disease using bi-cyclic peptides
Evotec and Sanofi's strategic collaboration to establish a new open innovation platform
F-star and Denali Therapeutics to develop a multi-specific platform for delivery of medicines across the blood-brain barrier
Neurocrine and AbbVie for elagolix in women’s health
Roche and Ionis Pharmaceuticals to develop antisense drugs for Huntington's disease
Novartis and the University of Pennsylvania for CAR-T medications in pediatric cancer patients
Financing Deal of the Year – Public
InflaRx’s $100m IPO and secondary offering
resTORbio’s $163m Series A to IPO
Polyphor’s CHF165m IPO
Horizon Discovery Group’s £80m public placing
Ablynx’s $200m US IPO on NASDAQ
Morphosys’ $239m overallotment issue and NASDAQ listing
Financing Deal of the Year – Private
Crescendo Biologics' $70m Series B financing
Enterprise Therapeutics’ £29m ($41m) Series B financing
BioNTech’s $270m Series A financing
AstraZeneca/MedImmune’s $250m financing for spin-out Viela Bio
PhoreMost’s £11m ($15m) Series A financing
NodThera’s £28m Series A financing
IQVIA’s Clinical Advance of the Year Award
Ablynx’s Phase III HERCULES study of caplacizumab for acquired thrombotic thrombocytopenic purpura
Alexion Pharmaceuticals' Phase III REGAIN study of Soliris (eculizumab) in myasthenia gravis
bluebird bio’s Northstar-2 study of LentiGlobin in beta-thalassemia
GW Pharmaceuticals’ Phase III GWPCARE4 trial of Epidiolex for refractory epilepsy
Ipca Laboratories Phase IV study of hydroxychloroquine in type 2 diabetes mellitus in India
Nanobiotix’s Phase I/II trial of nanomedicine NBTXR3 in head and neck cancer
Licensing Deal of the Year – Sponsored by Worldwide Clinical Trials
AiCuris and Merck & Co (MSD) for Prevymis (letermovir) for cytomegalovirus
AstraZeneca and Merck & Co (MSD) for Lynparza and selumetinib
AstraZeneca/Pearl and Avillion for PT027 in asthma
Emergent BioSolutions and Valneva for the Zika vaccine candidate VLA1601
F-star (through F-star Delta) and Merck KGaA for five bispecific antibodies in immuno-oncology
Halozyme and Bristol-Myers Squibb for the use of ENHANZE drug delivery technology in immuno-oncology drugs
Executive of the Year – For Large & Medium Cap Companies
Edwin Moses, CEO of Ablynx
John Maraganore, CEO of Alnylam
Alan Hirzel, CEO of Abcam
Jan van de Winkle, CEO of Genmab
Vas Narasimhan, CEO of Novartis
Niels Riedemann, CEO co-founder of InflaRx
Executive of the Year – For Small Cap & Private Pharma Companies
Eduardo Bravo, CEO of TiGenix
Jurgi Camblong, CEO and founder of SOPHiA GENETICS
Carl Firth, CEO and founder of ASLAN Pharmaceuticals
Antony Loebel, executive vice president, chief medical officer, head of global clinical development of Sunovion Pharmaceuticals
Amy Schulman, CEO and co-founder of Lyndra
Raman Singh, CEO of Mundipharma
WuXi AppTec’s Biotech Company of the Year Award
Genmab
AveXis
F-star
Neurocrine Biosciences
Bicycle Therapeutics
Diurnal Group
Business Development Team of the Year
AstraZeneca and Avillion partnership team
Bicycle Therapeutics’ business development team
CinnaGen’s business development team
Evotec’s business development team
F-star’s business development team
Rentschler Biopharma/Leukocare alliance business development team
Syneos Health's Best New Drug Award
TiGenix’s Alofisel (darvadstrocel)
Roche’s Hemlibra (emicizumab)
Novartis’s Kymriah (tisagenlecleucel)
Spark Therapeutics’ Luxturna (voretigene neparvovec-rzyl)
Kite Pharma/Gilead Sciences’ Yescarta (axicabtagene ciloleucel)
Natalia Kay
Tel: +44 (0) 20 7017 5173
Mobile +44 (0) 7917 265 637
Email: Natalia.kay@informa.com